Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Parmiani

Showing results (31-40 of 105) with videos related to

Pageof 11
Sort By:
Plos One|October 3, 2009
Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patientsElena Tassi, Marco Braga, Renato Longhi, et al.
Cancer Immunology, Immunotherapy : CII|October 13, 2006
Vaccination therapy in prostate cancerAndrea Marrari, Manuela Iero, Lorenzo Pilla, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 2012
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapyArianna Calcinotto, Matteo Grioni, Elena Jachetti, et al.
Cancer Research|April 19, 2006
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunityChiara Casati, Chiara Camisaschi, Francesca Rini, et al.
Oncoimmunology|April 9, 2016
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 studyCristina Maccalli, Diana Giannarelli, Filippo Capocefalo, et al.
Cancer Research|February 8, 2005
Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotypeMarialuisa Sensi, Gabriella Nicolini, Marina Zanon, et al.
Cancer Immunology, Immunotherapy : CII|November 11, 2008
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?Manuela Iero, Paola Filipazzi, Chiara Castelli, et al.
Cancer Research|September 20, 2006
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytesRoberta Valenti, Veronica Huber, Paola Filipazzi, et al.
Oncoimmunology|May 6, 2015
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanomaGiorgio Parmiani, Lorenzo Pilla, Angelo Corti, et al.
Cancer Immunology, Immunotherapy : CII|June 15, 2007
Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptideManuela Iero, Paola Squarcina, Pedro Romero, et al.
Pageof 11

Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Plos One|October 3, 2009
Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patientsElena Tassi, Marco Braga, Renato Longhi, et al.
Cancer Immunology, Immunotherapy : CII|October 13, 2006
Vaccination therapy in prostate cancerAndrea Marrari, Manuela Iero, Lorenzo Pilla, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 2012
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapyArianna Calcinotto, Matteo Grioni, Elena Jachetti, et al.
Cancer Research|April 19, 2006
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunityChiara Casati, Chiara Camisaschi, Francesca Rini, et al.
Oncoimmunology|April 9, 2016
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 studyCristina Maccalli, Diana Giannarelli, Filippo Capocefalo, et al.
Cancer Research|February 8, 2005
Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotypeMarialuisa Sensi, Gabriella Nicolini, Marina Zanon, et al.
Cancer Immunology, Immunotherapy : CII|November 11, 2008
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?Manuela Iero, Paola Filipazzi, Chiara Castelli, et al.
Cancer Research|September 20, 2006
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytesRoberta Valenti, Veronica Huber, Paola Filipazzi, et al.
Oncoimmunology|May 6, 2015
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanomaGiorgio Parmiani, Lorenzo Pilla, Angelo Corti, et al.
Cancer Immunology, Immunotherapy : CII|June 15, 2007
Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptideManuela Iero, Paola Squarcina, Pedro Romero, et al.
Pageof 11